SCHEMBL6750243

SCHEMBL6750243

CC(O[C]=O)S(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 6/20 0.44
CA2 P00918 6/20 0.44
CA12 O43570 4/20 0.44
CA9 Q16790 4/20 0.44
CA3 P07451 3/20 0.44
CA4 P22748 3/20 0.44
CA6 P23280 3/20 0.44
CA5A P35218 3/20 0.44
CA7 P43166 3/20 0.44
CA13 Q8N1Q1 3/20 0.44
CA14 Q9ULX7 3/20 0.44
CA5B Q9Y2D0 3/20 0.44
PSEN1 P49768 4/20 0.43
PSEN2 P49810 4/20 0.43
APH1B Q8WW43 4/20 0.43
NCSTN Q92542 4/20 0.43
APH1A Q96BI3 4/20 0.43
PSENEN Q9NZ42 4/20 0.43
ALDH1A1 P00352 4/20 0.42
CYP3A4 P08684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8549449 0.84 ENPP2 (0.41)
SCHEMBL21519825 0.84 CA2 (0.45) CA1CA2CA12CA9CA3
SCHEMBL1378451 0.84 CA2 (0.45) CA1CA2CA12CA9CA3
SCHEMBL2032391 0.81 CA12 (0.40) CA1CA2CA12CA9CA3
SCHEMBL5314145 0.78 CA1 (0.49) CA1CA2CA12CA9CA3
SCHEMBL217302 0.74 ALDH1A1 (0.54) CA1CA2CA12CA9CA3
SCHEMBL9043455 0.73 LMNA (0.50) CA1CA2CA9KMT2AMEN1
SCHEMBL9163505 0.72 HSD11B1 (0.38) ALDH1A1CYP3A4KDM4EHSD17B10KMT2A
SCHEMBL8662610 0.72 NPC1 (0.45) CA1CA2CA12CA9CA3
SCHEMBL21515839 0.71 CA1 (0.52) CA1CA2CA12CA9CA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040142946-A1 Modified nucleosides and nucleotides and use thereof CHATTOPADHYAYA JYOTI (SE) 2004-07-22 US claimed
EP-1332150-A1 MODIFIED NUCLEOSIDES AND NUCLEOTIDES AND USE THEREOF Chattopadhyaya, Jyoti (SE) 2003-08-06 EP claimed
WO-2002038578-A1 MODIFIED NUCLEOSIDES AND NUCLEOTIDES AND USE THEREOF CHATTOPADHYAYA JYOTI (SE) 2002-05-16 WO claimed
US-5721350-A Deuterated nucleosides CHATTOPADHYAYA JYOTI (SE) 1998-02-24 US claimed
EP-0648220-A1 DEUTERATED NUCLEOSIDES CHATTOPADHYAYA, Jyoti (SE) 1995-04-19 EP claimed
WO-1993025566-A1 DEUTERATED NUCLEOSIDES CHATTOPADHYAYA JYOTI (SE) 1993-12-23 WO claimed
US-5571313-A Ink-jet ink CANON KABUSHIKI KAISHA (JP) 1996-11-05 US disclosed
US-5547941-A VIRICIDES; USED IN TREATMENT OF HIV AND AIDS FARMITALIA CARLO ERBA S.R.L. (IT) 1996-08-20 US disclosed
EP-0699723-A2 Ink-jet ink CANON KABUSHIKI KAISHA (JP) 1996-03-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142946-A1 Modified nucleosides and nucleotides and use thereof RNASEH1, RNASEL, NSUN2 CA1 3818/4885CA2 2368/4885CA12 3292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.